Sophia Genetics (SOPH) Fundamental Analysis: Revenue, Earnings & Valuation

1.12 / 10

Underperform

Analysis concludes subpar fundamental quality (1.1/10). Favorable components: Revenue-MV and Operating revenue (YoY growth rate %), offset by weaknesses in Profit-MV and Net income-Revenue. Investment recommendation: challenging.

Analysis Checks(2/10)

Revenue-MV

Value-0.89

Score3/3

Weight-22.16%

1M Return3.03%

Net cash flow from operating activities / Operating revenue (%)

Value-46.45

Score1/3

Weight5.45%

1M Return-0.94%

Profit-MV

Value0.61

Score1/3

Weight10.00%

1M Return-1.48%

Net income-Revenue

Value-0.05

Score0/3

Weight15.22%

1M Return-2.56%

Non-current assets / Total assets (%)

Value39.23

Score1/3

Weight12.84%

1M Return-2.33%

Cash-UP

Value-0.13

Score0/3

Weight29.23%

1M Return-6.32%

Operating revenue (YoY growth rate %)

Value18.56

Score2/3

Weight2.19%

1M Return-0.38%

EBIT / Total operating revenue (%)

Value-96.81

Score1/3

Weight6.36%

1M Return-1.16%

Asset-MV

Value-0.72

Score1/3

Weight20.09%

1M Return-3.57%

Cash-MV

Value0.01

Score0/3

Weight20.77%

1M Return-3.50%

Is SOPH undervalued or overvalued?

SOPH scores 1.12/10 on fundamentals and holds a Premium valuation at present. Backed by its -110.00% ROE, -102.24% net margin, -4.57 P/E ratio, 7.66 P/B ratio, and -23.16% earnings growth, these metrics solidify its Underperform investment rating.